STOCK TITAN

Insight Molecular Diagnostics prices stock offering at $1.75

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. (IMDX) priced an underwritten public offering of 8,296,429 common shares at $1.75 each and pre-funded warrants for up to 275,000 shares at $1.7499 each. All securities are being sold by the company. It also granted the underwriter a 30-day option for up to 1,285,714 additional shares at the public offering price, less underwriting discounts and commissions.

Gross proceeds are expected to be approximately $15.0 million, before underwriting discounts, commissions and estimated expenses. The company intends to use net proceeds for working capital and general corporate purposes, including research and development in the transplantation category. The offering is expected to close on or about November 18, 2026, subject to customary closing conditions. The warrants are immediately exercisable at $0.0001 per share, subject to a 4.99% beneficial-ownership limit or 9.99% at a holder’s election.

Filing Explained

Because iMDx is the seller, completing the priced offering would add the offered common shares to the share count and reduce existing holders’ ownership percentages; exercising the pre-funded warrants could add further shares, subject to the stated ownership caps.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Common shares offered 8,296,429 shares Priced at $1.75 per share.
Shares issuable under pre-funded warrants Up to 275,000 shares Priced at $1.7499 per warrant.
Common share offering price $1.75 per share Public offering price.
Pre-funded warrant offering price $1.7499 per warrant Public offering price.
Underwriter option Up to 1,285,714 shares 30-day option at the public offering price, less underwriting discounts and commissions.
Expected gross proceeds Approximately $15.0 million Before underwriting discounts, commissions and estimated expenses.
Pre-funded warrant exercise price $0.0001 per share Exercise price for each warrant share.
Beneficial-ownership limit 4.99%; 9.99% at the holder’s election Limit on warrant exercises based on beneficial ownership immediately after exercise.
Pre-Funded Warrants financial
"pre-funded warrants to purchase up to 275,000 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
underwriting discounts and commissions financial
"before deducting underwriting discounts and commissions"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.
shelf registration statement regulatory
"A shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
beneficially own financial
"would beneficially own more than 4.99%"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
customary closing conditions financial
"subject to customary closing conditions"
"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.
Offering Type underwritten public offering (primary)
Securities Offered Common stock and pre-funded warrants to purchase common stock
Price Range $1.75 per common share; $1.7499 per pre-funded warrant
Offering Amount 8,296,429 common shares and pre-funded warrants to purchase up to 275,000 shares; a 30-day option for up to 1,285,714 additional shares; approximately $15.0 million expected gross proceeds
Use of Proceeds Working capital and general corporate purposes, including research and development in the transplantation category

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares and pre-funded warrants is IMDX offering, and at what prices?

IMDX priced 8,296,429 common shares at $1.75 each and pre-funded warrants to purchase up to 275,000 common shares at $1.7499 per warrant. The company is selling all of the securities in the offering.

How much does IMDX expect to raise, and how will it use the proceeds?

Gross proceeds are expected to be approximately $15.0 million, before underwriting discounts, commissions and estimated expenses. The company intends to use the net proceeds for working capital and general corporate purposes, including research and development in the transplantation category.

What are the exercise terms for IMDX’s pre-funded warrants?

The warrants are immediately exercisable upon issuance at $0.0001 per share and may be exercised until exercised in full. A holder may not exercise them if that would result in the holder and its affiliates and attribution parties beneficially owning more than 4.99% of outstanding common stock, or 9.99% at the holder’s election.

What restrictions does the IMDX underwriting agreement place on other share offerings?

For 90 days following the November 17, 2026 agreement date, the company may not dispose of or announce an offering of shares or securities convertible into or exchangeable for common stock, or submit or file related registration statements or prospectuses, subject to certain exceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001642380 0001642380 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

Insight Molecular Diagnostics Inc.

(Exact name of Registrant as specified in its charter)

 

California   1-37648   27-1041563
(State or other jurisdiction
of incorporation)
  (Commission
File No.)
  (IRS Employer
Identification No.)

 

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

 

(615) 255-8880

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, no par value   IMDX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 17, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as underwriter (the “Underwriter”), relating to an underwritten public offering (the “Offering”) of (i) 8,296,429 shares (the “Shares”) of the Company’s common stock, no par value per share (“Common Stock”), and (ii) pre-funded warrants to purchase up to 275,000 shares of Common Stock (the “Pre-Funded Warrants”), at a public offering price of $1.75 per Share and $1.7499 per Pre-Funded Warrant (which represents the per share offering price for the Shares less the $0.0001 per share exercise price for each Pre-Funded Warrant). Pursuant to the Underwriting Agreement, the Company also granted the Underwriter a 30-day option to purchase up to an additional 1,285,714 shares of the Common Stock at the public offering price, net of underwriting discounts and commissions. The Offering is expected to close on or about November 18, 2026 (the “Closing Date”), subject to the satisfaction or waiver of customary closing conditions.

 

All of the securities in the Offering are being sold by the Company.

 

Aggregate gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting underwriting discounts and commissions and estimated expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.

 

The Underwriting Agreement additionally contains customary representations, warranties and covenants made by the Company, including an agreement by the Company that the Company may not dispose of, or announce the offering of, or submit or file any registration statement, prospectus or prospectus supplement in respect of, any shares or securities convertible into or exchangeable for Common Stock until 90 days following the date of the Underwriting Agreement, subject to certain exceptions.

 

The Underwriting Agreement also provides for customary indemnification by each of the Company and the Underwriters for losses or damages arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions.

 

Each Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may be exercised at any time until exercised in full. A holder may not exercise any portion of its Pre-Funded Warrants to the extent that the holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise.

 

The Offering is being made pursuant to the Company’s registration statement on Form S-3 (File No. 333-281159) filed with the Securities and Exchange Commission (the “SEC”) on August 1, 2024, and declared effective on August 7, 2024, a base prospectus dated August 7, 2024, a preliminary prospectus supplement, dated November 16, 2026 and a prospectus supplement, dated November 17, 2026 and filed with the SEC on November 18, 2026.

 

The foregoing descriptions of the material terms of the Underwriting Agreement and Pre-Funded Warrants do not purport to be complete and are each qualified in their entirety by reference to the Underwriting Agreement and form of Pre-Funded Warrant, respectively, which are filed as Exhibit 1.1 and Exhibit 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

 

The legal opinion, including the related consent, of Haynes and Boone, LLP relating to the issuance and sale of the Shares is filed as Exhibit 5.1 hereto.

 

Item 8.01 Other Events.

 

On November 16, 2026, the Company issued a press release announcing the launch of the Offering. On November 17, 2026, the Company issued a press release announcing the pricing of the Offering. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
1.1*   Underwriting Agreement, dated November 17, 2026, by and between Insight Molecular Diagnostics Inc. and Lake Street Capital Markets, LLC.
4.1   Form of Pre-Funded Warrant.
5.1   Opinion of Haynes and Boone, LLP.
23.1   Consent of Haynes and Boone, LLP (included in Exhibit 5.1).
99.1   Press Release, dated November 16, 2026.
99.2   Press Release, dated November 17, 2026.
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

* Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will provide a copy of such omitted materials to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSIGHT MOLECULAR DIAGNOSTICS INC.
     
Date: November 18, 2026 By: /s/ Peter Hong
  Name: Peter Hong
  Title: Vice President, General Counsel

 

 

 

 

Exhibit 99.1

 

 

Insight Molecular Diagnostics Announces Proposed Public Offering

 

NASHVILLE, Tenn. – November 16, 2026 – Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock offered in the public offering (including shares issuable upon exercise of the pre-funded warrants). The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

 

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited to research and development in the transplantation category.

 

Lake Street Capital Markets is acting as the sole managing underwriter for the offering.

 

A shelf registration statement on Form S-3 (File No. 333-281159) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. The offering is being made only by means of a prospectus supplement and accompanying prospectus. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, by visiting the SEC’s website at http://www.sec.gov or by contacting: Lake Street Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, MN 55402, by telephone at (612) 326-1305 or e-mail at syndicate@lakestreetcm.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Insight Molecular Diagnostics Inc.

 

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.

 

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These statements include those pertaining to the consummation of the offering and the satisfaction of customary closing conditions related to the offering and the use of proceeds therefrom. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, the risk that the FDA may not accept our response to its request for additional information, may request further information, or may not grant marketing authorization for GraftAssureDx on the expected timeline or at all, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third-party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other cautionary statements found in Insight Molecular Diagnostics’ SEC filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.  

 

Investor Contact:

 

Alexandra Grossman

LifeSci Advisors LLC

imdx@lifesciadvisors.com

 

 

 

 

Exhibit 99.2

 

 

Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering

 

NASHVILLE, Tenn. – November 17, 2026 – Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced the pricing of its underwritten public offering of 8,296,429 shares of its common stock at a price to the public of $1.75 per share and pre-funded warrants to purchase up to 275,000 shares of common stock at a price to the public of $1.7499 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are being sold by iMDx. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 1,285,714 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about November 18, 2026, subject to customary closing conditions.

 

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including but not limited to research and development in the transplantation category.

 

Lake Street Capital Markets is acting as the sole managing underwriter for the offering.

 

A shelf registration statement on Form S-3 (File No. 333-281159) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus supplement and an accompany prospectus related to the offering, when available, can be obtained for free by visiting the SEC’s website at http://www.sec.gov or by contacting: Lake Street Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, MN 55402, by telephone at (612) 326-1305 or e-mail at syndicate@lakestreetcm.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Insight Molecular Diagnostics Inc.

 

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.

 

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These statements include those pertaining to the consummation of the offering and the satisfaction of customary closing conditions related to the offering and the use of proceeds therefrom. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, the risk that the FDA may not accept our response to its request for additional information, may request further information, or may not grant marketing authorization for GraftAssureDx on the expected timeline or at all, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third-party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other cautionary statements found in Insight Molecular Diagnostics’ SEC filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.  

 

Investor Contact:

 

Alexandra Grossman

LifeSci Advisors LLC

imdx@lifesciadvisors.com

 

 

 

Filing Exhibits & Attachments

12 documents

Keep reading